epidermal growth factor receptor tyrosine kinase inhibitor - Globe Thesis

Keyword [epidermal growth factor receptor tyrosine kinase inhibitor] Result: 21 - 40 \| Page: 2 of 4
21.	The Efficacy Comparison Of Icotinib And Gefitinib In Stage Ⅳ Lung Adenocarcinoma Patients With EGFR Sensitive Gene Mutation
22.	Clinical Study Of Modified Xiaoji Decoction Combines With Cytokine Induced Killer Cells And Erlotinib In The Treating Of Advanced Non-small Cell Lung Cancer
23.	Hepatocyte Growth Factor Reduces Sensitivity To The Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Gefitinib,in Lung Adenocarcinoma Cells Harboring Wild-TypeEGFR
24.	Efficiency And Safety Of Intercalated Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
25.	Circulating Plasma MicroRNAs As Potential Markers To Identify EGFR Mutation Status And To Monitor Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor Treatment In Patients With Advanced Non-small Cell Lung Cancer
26.	The Correlation Between EGFR Mutation Status And EGFR-TKI Efficacy In Non-small Cell Lung Cancer
27.	Treatment And Prognosis Analysis Of 60 Cases Of Different EGFR Mutations Status In Non-small Cell Lung Cancer With Brain Metastasis
28.	Investigation Of EGFR Gene Mutation In Lung Squamous Cell Carcinoma And The Effect Of EGFR-TKI Treatment On Advanced EGFR Mutation
29.	The Clinical Observation Of EGFR-TKI Rechallenge With Antiangiogenic Agents In Advanced NSCLC
30.	The Differences Of Efficacy Of Chemotherapy And Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor In Advanced Lung Adenocarcinoma Patients Harboring 19del And L858R Mutation
31.	Comparison Of The Clinical Outcome Of Gefitinib For Advanced Lung Adenocarcinoma With Positive Epidermal Growth Factor Receptor Mutated In Exon 21 Or 19 Del Between Patients Treated With First And Second Line Therapy
32.	Clinical Studies And Prognostic Analysis Of Leptomeningeal Metastases From Lung Cancer And Adenosquamous Lung Carcinoma
33.	Establishment Of Third Generation EGFR-TKI Osimertinib Acquired Resistant NSCLC Cell Line And Preliminary Study On Resistance Mechanism
34.	The Role Of Local Ablation Thepray For Advanced EGFR-mutant NSCLC Patients With Oligometastatic Disease Or Oligoprogressive Disease
35.	The Role Of Rerum VEGF In Determining EGFR-TKI Acquired Resistance In Lung Adenocarcinoma
36.	Serum Albumin And CEA Are Associated With Prognosis Of EGFR-TKI Treatment In Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
37.	Correlation Between PD-L1 Expression And EGFR Mutation In Lung Adenocarcinoma
38.	Modulation Of ALDHA1 Activity Reverses Stem-like Cell-mediated EGFR-TKI Resistance In NSCLC
39.	Clinical Characteristics And Molecular Mechanism Of Transformation From Adenocarcinoma To Small-cell Lung Cancer In EGFR Mutant Patients After EGFR-TKI
40.	Efficacy Of Chemotherapy And Oral Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor In Lung Adenocarcinoma
<<First <Prev Next> Last>> Jump to